rC3-1

rC3-1 is a recombinant protein-based complement inhibitor developed by Amyndas Pharmaceuticals. It is designed to target the third component of complement (C3), a central hub in the complement activation cascade. By binding to C3 and its activation fragments, rC3-1 prevents the formation of C3 and C5 convertases, thereby inhibiting both the classical and alternative pathways of complement activation. This mechanism is intended to mitigate complement-mediated inflammation and tissue damage in various pathological conditions. The drug has been explored for potential applications in complement-driven diseases such as periodontitis, paroxysmal nocturnal hemoglobinuria (PNH), and C3 glomerulopathy (C3G).

Other names

recombinant C3-targeted inhibitorrecombinant human C3-derivative